In last trading session, Regenxbio Inc (NASDAQ:RGNX) saw 0.54 million shares changing hands with its beta currently measuring 1.32. Company’s recent per share price level of $18.09 trading at -$0.93 or -4.89% at ring of the bell on the day assigns it a market valuation of $886.23M. That closing price of RGNX’s stock is at a discount of -59.2% from its 52-week high price of $28.80 and is indicating a premium of 34.6% from its 52-week low price of $11.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.48 million shares which gives us an average trading volume of 751.08K if we extend that period to 3-months.
Regenxbio Inc (NASDAQ:RGNX) trade information
Upright in the red during last session for losing -4.89%, in the last five days RGNX remained trading in the red while hitting it’s week-highest on Tuesday, 04/09/24 when the stock touched $18.09 price level, adding 8.5% to its value on the day. Regenxbio Inc’s shares saw a change of 0.78% in year-to-date performance and have moved -5.63% in past 5-day. Regenxbio Inc (NASDAQ:RGNX) showed a performance of -19.49% in past 30-days. Number of shares sold short was 3.95 million shares which calculate 4.06 days to cover the short interests.
Regenxbio Inc (RGNX) estimates and forecasts
Statistics highlight that Regenxbio Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 7.61% of value to its shares in past 6 months, showing an annual growth rate of 33.89% while that of industry is 13.30. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 17.60% in the current quarter and calculating 26.50% increase in the next quarter. This year revenue growth is estimated to rise 48.10% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $23.52 million for the same. And 8 analysts are in estimates of company making revenue of $25.23 million in the next quarter that will end on Jun 2024.
In 2024, company’s earnings growth rate is likely to be around 31.73% while estimates for its earnings growth in next 5 years are of 13.60%.
RGNX Dividends
Regenxbio Inc is more likely to be releasing its next quarterly report in May and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Regenxbio Inc (NASDAQ:RGNX)’s Major holders
Insiders are in possession of 7.18% of company’s total shares while institution are holding 81.63 percent of that, with stock having share float percentage of 87.94%. Investors also watch the number of corporate investors in a company very closely, which is 81.63% institutions for Regenxbio Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at RGNX for having 8.27 million shares of worth $165.3 million. And as of Jun 29, 2023, it was holding 18.81% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 4.34 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 9.87% of outstanding shares, having a total worth of $86.76 million.
On the other hand, iShares Core S&P Smallcap ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2023, the former fund manager was holding 2.73 million shares of worth $44.95 million or 6.21% of the total outstanding shares. The later fund manager was in possession of 1.32 million shares on Aug 30, 2023, making its stake of worth around $23.42 million in the company or a holder of 3.01% of company’s stock.
